Multiple Myeloma
Dec 13, 2023
DARZALEX FASPRO Quadruplet Regimen Demonstrates Striking Advancements in Treatment Outcomes for Newly Diagnosed Multiple Myeloma Eligible for Transplantation
Date of Abstract presentation12th December 2023IndicationsMultiple MyelomaAbstract NumberLBA1Abstract typeOral The PERSEUS study is being conducted in collaboration with the European Myeloma Network as a sponsor. PERSEUS is an ongoing, randomized, open-label, Phase III study comparing the efficacy and safety of ...
Read More...
Dec 13, 2023
Cilta-cel Demonstrates Prolonged and Deep Responses across Advanced Treatment Lines, Signifying Potential in Early Lenalidomide-Refractory Multiple Myeloma
Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1063Abstract typeOral According to the findings presented at the ASH 2023, the CARTITUDE-4 trial included a cohort of 419 patients. As of the clinical cut-off, 99 patients in the CARVYKTI arm and 66 in the standard of care (...
Read More...
Dec 13, 2023
Cilta-Cel’s Prolonged Impact: Deep Responses and Safety Insights from Earlier Lines of Therapy in Multiple Myeloma
Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1021Abstract typeOral CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s T cells with a transge...
Read More...
Oct 03, 2023
AbbVie Presents Phase III CANOVA Study Results; Novartis’ Iptacopan Shows Promise in Phase III Study; Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer; FDA Issues Complete Response Letter for Lebrikizumab; Nedosiran Approveed for Primary Hyperoxaluria Type 1; Orphan Drug Designation to BDC-1001 for Gastric Cancers
AbbVie Presents Results from Phase III CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie has released findings from its Phase III CANOVA trial, which assessed the safety and effectiveness of venetoclax (marketed as VENCLEXTA®/VENCLYXTO®) in combination with dexamethasone ...
Read More...
Aug 29, 2023
FDA Approves BMS’s Reblozyl for MDS; FDA Awards Orphan Drug Designation to NXC-201; Janssen Submits Supplemental NDA for Full Approval of BALVERSA; FDA Grants Fast Track Status to ALE.C04; FDA Orphan Drug Designation to Faron’s Bexmarilimab; FDA Clears IND Application for AHB-137
FDA Approves Bristol Myers Squibb’s Reblozyl as First-Line Treatment of Anemia in Adults with Lower-Risk MDS Who May Require Transfusions Bristol Myers Squibb announced that the Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt) for the treatment of anemia in adult patients with very l...
Read More...
Aug 15, 2023
J&J’s 2-in-1 Tablet for Prostate Cancer; FDA Approves TALVEY for Heavily Pretreated Multiple Myeloma; PDS Biotech Updated on VERSATILE-003 Trial; FDA Issues CRL to NDA for Avasopasem in Radiotherapy-Induced Severe Oral Mucositis in HNC; FDA Orphan Drug Designation to Genprex’s REQORSA; FDA Orphan Drug Designation to Bloomsbury’s BGT-OTCD
FDA Clears J&J’s 2-in-1 Tablet for Prostate Cancer Johnson & Johnson's Janssen Pharmaceutical Companies stated that the US Food and Drug Administration (FDA) had approved AKEEGA (niraparib and abiraterone acetate), the first-and-only dual-action tablet combining a PARP inhibitor including abiraterone ace...
Read More...
Feb 27, 2023
Minimal Residual Disease (MRD) Testing: A Path to Cure Cancer?
Measurable or Minimal Residual Disease (MRD) is a term often used when treating patients with blood cancers. MRD is a small number of cancer cells left in the body after cancer treatment, and these cells can potentially cause relapse in these patients. The number of remaining cells is often too small to cause any s...
Read More...
Feb 14, 2023
Leo Pharma’s Hand Eczema Clinical Trial Updates; GSK’s PD-1 inhibitor Jemperli Approval; Roche Announces Phase III Result of Vabysmo; FDA Accepts NDA for Aldeyra’s reproxalap; RMAT and Fast Track Designations to IASO Bio’s CT103A; Orphan Drug Designation to Jubilant Therapeutics’s JBI-778
Leo Pharma Announces Positive Results of Phase III Hand Eczema Clinical Trial LEO Pharma A/S, a global leader in medical dermatology, announced that the DELTA 2 trial yielded positive results. DELTA 2 is the second of two pivotal phase III clinical trials involving delgocitinib cream, an investigational topical ...
Read More...
Jan 31, 2023
Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval
FDA Approves Eli Lilly’s Jaypirca for Relapsed Mantle Cell Lymphoma Eli Lilly has received FDA approval for Jaypirca, a non-covalent BTK inhibitor, in relapsed mantle cell lymphoma (MCL) patients who have relapsed after treatment with other drugs in the class. Adult MCL patients who have previously received at l...
Read More...
Nov 08, 2022
Amgen’s Olpasiran Candidate; GSK’s Novel Antibiotic for Urinary Tract Infections; AstraZeneca and Sanofi’s Beyfortus Approval; FDA Orphan Designation to Anavex’s Anavex2-73; FDA Rare Pediatric Disease Designation to Sensorion’s OTOF-GT; GSK’s Blenrep Fails in Phase III Trial in R/R Multiple Myeloma
Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate Amgen has reported encouraging mid-stage results for its olpasiran candidate for lowering lipoprotein(a) - a risk factor for atherosclerotic cardiovascular disease - and now plans to move forward with a phase III program as soon as possi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
